Research Library

Using charts, figures and graphs of this survey data originally created by former career intelligence analyst Brian C. Bennett and updated by the Drug Policy Program, this issue brief offers an overview of drug use trends in America over the last four decades. The brief is part of a larger online project chronicling the pattern of the use and abuse of individual drugs over (in most cases) more than 40 years.

The percentage of Hispanics in Texas without health insurance has dropped by 30 percent since the Affordable Care Act (ACA) went into effect, but almost one-third of Hispanic Texans ages 18 to 64 remain uninsured.

The percentage of Texans without health insurance has dropped by 30 percent since the Affordable Care Act (ACA) went into effect, cutting the state’s uninsured rate below 1999 levels.

This study assesses the attitudes of women in Jordanian maternity clinics with regard to CB banking and transplantation.

State "right to try" laws can give terminally ill patients early access to experimental drugs and medical devices — but they arguably make safety and efficacy secondary to speedy access.

This issue brief argues that continued investments in global health and the study of emerging pathogens could yield better tools to fight infectious diseases like the Zika virus long before they become a problem in the developed world.

Baker Institute Policy Report #64 highlights some of the central ethical issues pertaining to NTD policy development and argues that ethical considerations should be included in the policy development process.

Baker Institute Policy Report #65 summarizes the key findings of the Baker Institute conference "The United States and Mexico: Addressing a Shared Legacy of Neglected Tropical Diseases and Poverty."

This policy brief urges collaboration between the United States and Mexico to address widespread epidemics of mosquito-transmitted diseases like West Nile, dengue and chikungunya in both countries. Such policy development should focus on vector control programs, public awareness and the development of vaccines to curb the spread of these diseases.

This journal article examines the risks patients face in seeking experimental stem cell-based interventions from clinics outside the United States. The authors advocate for new public policies that encourage patients to remain in clinical trials in the U.S.